Navigation Links
Omeros Appoints New Vice President of Clinical Development
Date:8/5/2009

SEATTLE, Aug. 5 /PRNewswire/ -- Omeros Corporation today announced the appointment of Stephen R. Murray, M.D., Ph.D. as Vice President of Clinical Development. Dr. Murray will oversee clinical trial strategies and protocols at Omeros, and currently is leading the ongoing clinical studies for Omeros' PharmacoSurgery(TM) product candidates. These include OMS103HP, the Company's lead candidate being evaluated in a Phase 3 clinical program for improved joint function and pain reduction following arthroscopic surgery, OMS302 in a Phase 2 program for use in cataract surgery, and OMS201 in a Phase 1/2 program for use in uroendoscopy.

"Dr. Murray brings a wealth of experience in the pharmaceutical industry, having successfully directed a number of development programs in both large and small pharmaceutical companies," said Gregory A. Demopulos, M.D., Chairman & CEO of Omeros. "Dr. Murray will work closely with our team members to continue building the long-term value of Omeros and our products."

"Omeros is poised to deliver important new treatments to patients through its PharmacoSurgery platform," said Dr. Murray. "In addition, we have several preclinical central nervous system and inflammation programs that have the potential to address significant unmet medical needs. This is an important time for Omeros and I'm excited to play a role here."

Prior to Omeros, Dr. Murray served in various positions, most recently as Chief Medical Officer at Memory Pharmaceuticals, a biopharmaceutical company that developed treatments for central nervous system disorders and was acquired by Hoffman-La Roche Inc. in January 2009. Before that, Dr. Murray held various positions at Pfizer Global Pharmaceuticals, including senior medical director and therapeutic team leader for schizophrenia. Dr. Murray received his M.D. and Ph.D. in molecular and cellular biology from the Medical University of South Carol
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
2. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
3. Omeros and BlueCrest Announce $20 Million Debt Facility
4. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
5. Omeros Appoints David A. Mann to its Board of Directors
6. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
7. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
8. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
9. Brookstone Pharmaceuticals Appoints New Corporate Position
10. PDI Appoints Gerald P. Belle as Lead Independent Director
11. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  MiMedx Group, Inc. (NASDAQ: ... of patent protected regenerative biomaterials and bioimplants processed ... another peer-reviewed clinical study.    The ... Controlled Clinical Trial Evaluating the Use of ... Multi-layer Compression Therapy vs. Multi-layer Compression Therapy Alone ...
(Date:9/17/2014)... Terracon Corporation has announced the introduction of a ... This addition to the company’s industry-leading line of custom ... available in 125 or 250 gallon capacities. It ... or less. , The new pre-engineered TerraPure tank offers ... TerraPure tank line – plus quick turnaround. An ...
(Date:9/17/2014)... , Sept. 17, 2014 Veracyte, Inc. ... company pioneering the field of molecular cytology, today announced ... officer. Mr. Hall joined Veracyte in 2010 ... entry into endocrinology. Since 2012, he has led sales, ... managed care and billing functions. As chief operating officer, ...
(Date:9/17/2014)... , September 17, 2014 ... mode of action from a truly novel ... MGB Biopharma, a biopharmaceutical company ... announces today that it has secured £4.0m ... lead antibacterial, MGB-BP-3, against a range of ...
Breaking Biology Technology:MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Stock Exchange Symbol: MSEDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), announced that effective on ... purchase warrants, each of which entitles the holder to ... of $5.00 per share, will be extended from March ...
... B.C. Technology Promises to Revolutionize Food Processing, ... Corporation (TSX-V: ENW) ("EnWave" or "the Company") today ... of its continuous nutraREV(TM) food dehydration equipment to ... of B.C.,s largest blueberry producers. With this sale, ...
... of "In the Zone for UC" Campaign, Centocor Ortho ... Colitis Foundation of America for Each Point Pisani Scores ... Ortho Biotech Inc. announced today a partnership with professional ... colitis (UC) and funding to support continued education and ...
Cached Biology Technology:BioMS Medical warrant extension 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 2Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 3Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 4
(Date:9/16/2014)... us that we inherit certain traits from our parents ... how these genes play out by taking certain drugs ... exactly what a team of researchers at the Boston ... research of epigenetics research. , Epigenetics regulates gene ... and histone proteins, which prevent permanent mutations or alterations ...
(Date:9/16/2014)... spelled doom for the dinosaurs 66 million years ago ... much greater extent than their deciduous peers, according to ... published in the journal PLOS Biology . ... thousands of fossilized leaves of angiosperms flowering ... reconstruct the ecology of a diverse plant community thriving ...
(Date:9/16/2014)... interaction between viruses, bacteria, and their environment is ... collaboration between Matthew Sullivan, associate professor in the ... Biology and Steven Hallam from the University of ... are drivers of nutrient and energy cycles that ... is changing, so are the environments these bacteria ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3
... has found all forms of tobacco exposure, whether that be ... of heart attack. , The study by professors Salim Yusuf ... Medicine at McMaster University and Hamilton Health Sciences in Hamilton, ... In collaboration with colleagues from 52 countries, they calculated the ...
... Researchers have found that abnormal stimulation of a ... cells in adults causes invasive tumor-like growths in ... to regress--a finding the researchers said suggests a ... called malignant gliomas. , Arturo Alvarez-Buylla and Erica ...
... savannas contain 70% of the world's plants and are critical ... project involving researchers from the Leeds Earth and Biosphere Institute ... sensitive areas. , The researchers think we may be at ... the rainforests to shrink, so increasing the amount of carbon ...
Cached Biology News:Global study shows all tobacco bad for the heart 2Global study shows all tobacco bad for the heart 3Possible birthplace of malignant brain tumors identified 2The vicious cycle of rainforest destruction 2
... shakers have the durability to ... 3-high, and the uniformity and ... shake" applications. Heavily built ... our stackers are designed for ...
CQCS kit for first KR 4i , (first unit)....
Multidrop Micro high speed 1 l bulk reagent dispenser rapidly, precisely and accurately dispenses microvolumes of 1-50 l into 384- and 96-well microplates....
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
Biology Products: